Genomics in Cancer Care Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Instruments, Consumables, Services), By Technology (Genome Sequencing, PCR, Microarray, Nucleic Acid Extraction and Purification, Others), By Application (Diagnostics, Personalized Medicine, Drug Discovery & Development, Research), By End User (Hospitals, Research Institutes & Academic Institutes, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 16.79 Billion
CAGR (2026-2031)	16.94%
Fastest Growing Segment	Personalized Medicine
Largest Market	North America
Market Size (2031)	USD 42.94 Billion

Market Overview

The Global Genomics in Cancer Care Market will grow from USD 16.79 Billion in 2025 to USD 42.94 Billion by 2031 at a 16.94% CAGR. Genomics in cancer care entails the analysis of patient and tumor genetic profiles to guide precision oncology through targeted therapies and personalized diagnostic strategies. The market is primarily propelled by the escalating incidence of oncological diseases, which necessitates accurate diagnostic tools, alongside the decreasing costs of next-generation sequencing technologies. According to the 'American Cancer Society', in '2025', '2,041,910 new cancer cases are projected to occur in the United States', highlighting the critical demand for advanced genomic interventions to manage this growing burden. These fundamental drivers support market stability and are distinct from evolving trends such as the integration of artificial intelligence in workflow automation.

However, a significant challenge impeding market expansion is the lack of standardized reimbursement policies and the high costs associated with comprehensive genomic profiling. Payers in many regions remain hesitant to provide full coverage for broad molecular diagnostic tests, creating substantial financial barriers for healthcare providers and patients. This economic uncertainty effectively limits the widespread adoption of these essential diagnostic solutions, particularly in developing healthcare infrastructures where resources are constrained.

Key Market Drivers

The continuous reduction in genome sequencing costs driven by advancements in Next-Generation Sequencing technologies serves as a primary engine for market growth. High-throughput sequencing platforms allow clinical laboratories to process genetic samples with greater speed and efficiency, thereby democratizing access to comprehensive genomic profiling. This increased capacity is evidenced by the rapid deployment of newer sequencing systems which are essential for processing high volumes of patient samples. According to Illumina, February 2024, in the 'Fourth Quarter and Full Year 2023 Financial Results', the company shipped 352 NovaSeq X instruments during the fiscal year, enabling laboratories to scale up genomic sequencing capabilities significantly. Such technological improvements reduce the barrier to entry for healthcare facilities, allowing them to integrate complex genomic data into routine oncology workflows without incurring prohibitive operational expenses.

Simultaneously, the emergence of non-invasive liquid biopsy solutions is reshaping clinical diagnostics by offering a viable alternative to traditional tissue biopsies. These blood-based tests detect circulating tumor DNA to identify genetic mutations, facilitating early detection and continuous monitoring of treatment response. According to Guardant Health, July 2024, in the 'FDA Approval of Shield Blood Test' announcement, the Shield test demonstrated 83% sensitivity for the detection of colorectal cancer, illustrating the clinical efficacy of blood-based genomic testing. This shift toward accessible testing is crucial as the global burden of disease intensifies; according to the World Health Organization, in 2024, new cancer cases are predicted to rise by 77% to reach 35 million by 2050. Consequently, the scalability of liquid biopsies directly addresses the need for mass screening tools capable of managing this increasing patient population.

Download Free Sample Report

Key Market Challenges

The lack of standardized reimbursement policies and the high costs associated with comprehensive genomic profiling significantly hamper the growth of the Global Genomics in Cancer Care Market. Healthcare providers frequently hesitate to order these advanced diagnostic tests due to inconsistent coverage criteria across different payers, which creates uncertainty regarding payment and increases the administrative burden on medical facilities. This financial unpredictability effectively disrupts clinical workflows and reduces the overall volume of genomic testing, thereby limiting the generation of genetic data essential for precision oncology strategies.

Furthermore, the substantial economic burden placed directly on patients restricts the addressable market for these diagnostic solutions. High out-of-pocket expenses often force individuals to decline recommended genomic profiling, as they are compelled to prioritize funding for essential treatments over diagnostic insights. According to the 'American Association for Cancer Research', in '2025', 'more than 40% of patients with cancer in the United States exhaust their life savings within two years of treatment'. This severe financial toxicity demonstrates how cost barriers directly reduce patient access and adoption rates. Consequently, the market struggles to expand its reach into broader patient populations, stifling the potential revenue growth and adoption of genomic interventions in standard cancer care.

Key Market Trends

The integration of artificial intelligence into genomic workflows is transforming data interpretation by automating the analysis of massive datasets to identify actionable oncological biomarkers. This technology addresses manual variant curation bottlenecks, allowing researchers to efficiently correlate complex genetic profiles with therapeutic outcomes. The commercial traction of such intelligent systems is significant as laboratories seek to scale precision oncology operations. According to Tempus AI, February 2025, in the 'Fourth Quarter and Full Year 2024 Results', the company reported a full-year revenue of $693.4 million, representing a 30.4% year-over-year increase driven by the widespread adoption of its AI-enabled genomics platform. This uptake highlights the growing reliance on computational tools to enhance the speed and accuracy of diagnostic strategies.

Simultaneously, the emergence of long-read sequencing technologies is proving essential for detecting complex structural variants that traditional short-read platforms often miss. These systems sequence long DNA stretches without fragmentation, providing a complete picture of tumor heterogeneity and fusion genes which are critical for targeted treatment planning. The rapid adoption of this technology is evident in the rising utilization of high-throughput platforms designed for deep genomic investigation. According to Oxford Nanopore Technologies, March 2025, in the 'Annual results for the year ended 31 December 2024', revenue from the PromethION product range grew by 55.8% year-over-year, indicating a strong market shift toward native long-read capabilities. This trend empowers clinicians to uncover comprehensive structural data vital for developing novel cancer therapies.

Segmental Insights

Personalized Medicine represents the fastest-growing segment within the Global Genomics in Cancer Care Market due to the increasing adoption of genomic profiling for tailoring treatment plans. This growth is primarily driven by the rising approval of companion diagnostics and targeted therapies by regulatory authorities such as the U.S. Food and Drug Administration. These genomic tools allow clinicians to identify specific genetic mutations in tumors, enabling the selection of drugs that offer higher efficacy and reduced toxicity compared to traditional treatments. Consequently, the shift toward individualizing cancer management continues to accelerate the expansion of this market segment.

Regional Insights

North America holds a dominant position in the global genomics in cancer care market, driven by a well-established healthcare infrastructure and substantial investment in research and development. The region benefits from strong government support, exemplified by initiatives from the National Cancer Institute that promote precision medicine adoption. Furthermore, the presence of major biotechnology firms and a favorable regulatory framework provided by the U.S. Food and Drug Administration accelerates the approval and commercialization of genomic diagnostic tests. This combination of funding, regulatory clarity, and industry presence secures the region's market leadership.

Recent Developments

• In October 2024, Exact Sciences received approval from the FDA for its Cologuard Plus test, a next-generation multitarget stool DNA test designed for colorectal cancer screening. The company reported that this advanced iteration demonstrated 95% sensitivity for colorectal cancer and improved specificity, significantly outperforming standard fecal immunochemical tests in head-to-head studies. At the time of the announcement, the organization anticipated launching the product commercially in 2025, supported by Medicare coverage and inclusion in U.S. Preventive Services Taskforce guidelines. The improved test was engineered to minimize false positives, thereby reducing the burden of unnecessary follow-up colonoscopies for patients.
• In July 2024, Guardant Health announced that it received approval from the U.S. Food and Drug Administration (FDA) for its Shield blood test for colorectal cancer screening. This regulatory milestone established the product as the first blood test authorized as a primary screening option for colorectal cancer in adults aged 45 and older at average risk. The company highlighted that the test met the performance requirements for Medicare coverage, positioning it to improve screening adherence rates by offering a non-invasive alternative to traditional methods. The approval was based on results from a large-scale registrational study validating the test's sensitivity and specificity.
• In April 2024, QIAGEN launched a new series of products designed to advance cancer research, including the QIAcuity dPCR PanCancer Kits. These kits were developed to enable researchers to detect multiple hallmark mutations in EGFR and BRAF genes simultaneously with high sensitivity using digital PCR technology. The company also introduced new solutions for urine liquid biopsy and targeted RNA sequencing to assist in detecting minimal residual disease and monitoring treatment responses. These innovations were showcased at the American Association for Cancer Research Annual Meeting, reinforcing the organization's commitment to strengthening its portfolio in comprehensive genomic profiling and non-invasive testing.
• In March 2024, Thermo Fisher Scientific entered into a strategic collaboration with Bayer to develop next-generation sequencing-based companion diagnostic assays for precision cancer therapies. The partnership focused on utilizing the Ion Torrent Genexus Dx System to create decentralized genomic testing solutions capable of delivering rapid results from liquid and tissue samples in as little as 24 hours. The companies aimed to enhance patient access to targeted treatments by identifying those who would benefit from Bayer's growing portfolio of precision oncology drugs. This agreement underscored a shared commitment to advancing precision medicine through faster, more accessible, and locally administered diagnostic workflows.

Key Market Players

• Illumina Inc
• Agilent Technologies, Inc.
• Roche Diagnostics
• Cancer Genetics, Inc.
• Bio-Rad Laboratories Inc
• Sigma-Aldrich Corp
• QIAGEN NV
• GE Healthcare Inc
• Life Technologies Corp
• Quest Diagnostics Inc

By Product	By Technology	By Application	By End User	By Region
Instruments Consumables Services	Genome Sequencing PCR Microarray Nucleic Acid Extraction and Purification Others	Diagnostics Personalized Medicine Drug Discovery & Development Research	Hospitals Research Institutes & Academic Institutes Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Genomics in Cancer Care Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Genomics in Cancer Care Market, By Product:

• Instruments
• Consumables
• Services

• Genomics in Cancer Care Market, By Technology:

• Genome Sequencing
• PCR
• Microarray
• Nucleic Acid Extraction and Purification
• Others

• Genomics in Cancer Care Market, By Application:

• Diagnostics
• Personalized Medicine
• Drug Discovery & Development
• Research

• Genomics in Cancer Care Market, By End User:

• Hospitals
• Research Institutes & Academic Institutes
• Others

• Genomics in Cancer Care Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE